3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
16
Dermatologic
9
Thoracic
7
Tumor-Agnostic
3
Breast
3
Sarcoma
2
Gastrointestinal
2
Lymphoid
1
Endocrine
1
Conditions
Neuroendocrine Tumors
13
Pheochromocytoma
6
Carcinoma, Neuroendocrine
6
Somatostatinoma
5
Paraganglioma
4
Pituitary Neoplasms
3
Insulinoma
3
Glucagonoma
3
Gastrinoma
3
Zollinger-Ellison Syndrome
2
Vipoma
2
Paraganglioma, Extra-Adrenal
2
Pancreatic Neoplasms
2
Gastro-enteropancreatic neuroendocrine tumor
2
Carcinoma, Medullary
2
Carcinoma, Islet Cell
2
Carcinoid Tumor
2
Spinal Cord Neoplasms
1
Small Cell Lung Carcinoma
1
Rhabdoid Tumor
1
Prolactinoma
1
Optic Nerve Glioma
1
Oligodendroglioma
1
Non functioning pancreatic endocrine tumor
1
Neuroectodermal Tumors, Primitive
1
Neoplasms
1
Neoplasm Metastasis
1
Multiple Endocrine Neoplasia Type 2b
1
Multiple Endocrine Neoplasia Type 2a
1
Multiple Endocrine Neoplasia Type 1
1
Interventions
Doxorubicin
4
Sunitinib
3
Radiosurgery
3
Everolimus
3
pembrolizumab
2
exemestane
2
Tamoxifen
2
Specimen Handling
2
Octreotide
2
Magnetic Resonance Spectroscopy
2
Fulvestrant
2
Filgrastim
2
Biopsy
2
Bevacizumab
2
3-Iodobenzylguanidine
2
tislelizumab
1
surufatinib
1
romidepsin
1
regorafenib
1
penpulimab
1
pasireotide
1
mercaptoundecahydrododecaborate
1
lutetium Lu 177 dotatate
1
lanreotide
1
ganitumab
1
folfirinox
1
fludarabine phosphate
1
epothilone B
1
entrectinib
1
dostarlimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
Temozolomide
×
Endocrine
×
Clear all
NCT05858177
2023-05-15
MPPGL
Peking Union Medical College Hospital
Phase 2
Completed
62 enrolled